Cancer treatment returns to Israel

Israeli biotech CureTech developed pidilizumab cancer treatment which was sold to US biotech Medivation which the giant Pfizer took over last year. Pidilizumab is an orphan treatment (for rare brain stem cancer) and of no commercial interest to Pfizer. So CureTech has bought it back.

This entry was posted in Economy & Business. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *